Skip to main content
OpenTrials
Completed

NCT Number: NCT02160314

A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence

This study will evaluate the safety of the pessary device by objective evaluation of vaginal wall integrity and subjective assessment of comfort during in-use conditions.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • be female 18 years or older;
  • provide written informed consent prior to study participation and been given a signed copy;
  • be in generally good health as determined by the Investigator;
  • have a ≥ 3 month history of experiencing Stress Urinary Incontinence (SUI) per week (self reported);
  • be willing to use the pessary investigational device to control stress urinary incontinence;
  • be willing to comply with study requirements and instructions;

Exclusion criteria

  • are pregnant, lactating, or planning to become pregnant during the study;
  • within 3 months post partum;
  • intrauterine device (IUD) placement of less than 6 months;
  • has self-reported difficulty emptying her bladder;
  • a history of Toxic Shock Syndrome (TSS) or symptoms consistent with TSS;
  • experience difficulty inserting or wearing an intra-vaginal device, including a tampon;
  • vaginal surgery, perineal surgery, uterine surgery, or abortion (spontaneous or induced) within the past 3 months;
  • has any Screening laboratory value outside the laboratory reference range considered clinically significant by the Investigator and could impact the safety of the subject or the outcome of the study; or
  • for any reason, the Investigator decides that the subject should not participate in the study.

Treatment and study plan

Pessary

Device

disposable, single-use pessary

Absorbent pad

Device

Other names: placebo comparator

Primary outcomes

  1. Treatment-emergent Serious Adverse Event

    Time frame: 3 month

    proportion of intent-to-treat subjects who experience a treatment-emergent serious adverse event

Sponsors and collaborators

Lead sponsor

Procter and Gamble

Industry

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jun 10, 2014
Registry last updated
Feb 15, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.